Efficacy, safety, and tolerability of mometasone furoate in adult Japanese patients with mild asthma: open-label clinical trial findings

References

• Makino S, Adachi M, Ago Y, et al. Epidemiology of asthma. Int Arch Allergy Immunol 2005;136(Suppl. 1):5-13
   PubMedGoogle Scholar
• Makino S, Adachi M, Ago Y, et al. Pharmacologic control of asthma. Int Arch Allergy Immunol 2005;136(Suppl. 1):14-49
   PubMedGoogle Scholar
• Humbert M. The right tools at the right time. Chest 2006;130:29S-40S
   PubMed Web of Science ®Google Scholar
• Godard P, Huas D, Sohier B, et al. [Asthma control in general practice: a cross-sectional survey of 16,580 patients]. Presse Med 2005;34:1351-7
   PubMed Web of Science ®Google Scholar
• Adachi M, Ohta K, Morikawa A, et al. [Changes in asthma insights and reality in Japan (AIRJ) in 2005 since 2000]. Arerugi 2008;57:107-20
   PubMedGoogle Scholar
• Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 2001;163:924-9
   PubMed Web of Science ®Google Scholar
• Bender BG, Long A, Parasuraman B, et al. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol 2007;98:322-8
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2006. Available at: http://www.ginaasthma.org [Last accessed 19 October 2008]
   Google Scholar
• Data on file (Comparison study of potency between MF-DPI and BDP: 20090521U). Schering-Plough K.K., Osaka, Japan
   Google Scholar
• Data on file (Phase II dose-finding study: 200905019U). Schering-Plough K.K., Osaka, Japan
   Google Scholar
• Yamamura Y, Mitsui S, Suto M, et al. Report of decisions of the committee on the criteria for the evaluation of severity of adult bronchial asthma of the Japan Allergy Society. Jpn J Allergol 1983;32:1186-99
   Google Scholar
• Miyamoto T, Takao S, Tomioka H, et al. Report of the committee for re-evaluation of the criteria for the evaluation of severity of bronchial asthma. Jpn J Allergol 1994;43:71-80
   Google Scholar
• Miyamoto T, Akiyama K, Adachi M, et al. [An open-label comparative non-inferiority study of mometasone furoate DPI versus fluticasone propionate DPI in adult patients with bronchial asthma]. Allergol Immunol 2009;16:716-31
   Google Scholar
• Data on file (High-dose study: 200905017U). Schering-Plough K.K., Osaka, Japan
   Google Scholar
• Miyamoto T, Akiyama K, Adachi M, et al. [Long-term safety and efficacy study of mometasone furoate dry powder for inhalation in the treatment of bronchial asthma in adult patients]. Allergol Immunol 2009;16:732-45
   Google Scholar
• Bensch GW, Prenner B, Berkowitz R, et al. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006;96:533-40
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999;93:603-12
   PubMed Web of Science ®Google Scholar
• Bousquet J, D’Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000;16:808-16
   PubMed Web of Science ®Google Scholar
• Corren J, Berkowitz R, Murray JJ, et al. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003;57:567-72
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005;21:1281-9
   PubMed Web of Science ®Google Scholar
• Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000;106:485-92
   PubMed Web of Science ®Google Scholar
• Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000;84:417-24
   PubMed Web of Science ®Google Scholar
• Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001;86:36-43
   PubMed Web of Science ®Google Scholar
• Makino S, Adachi M, Ago Y, et al. Definition, diagnosis, disease types, and classification of asthma. Int Arch Allergy Immunol 2005;136(Suppl. 1):3-4
   PubMedGoogle Scholar
• Miyamoto T, Sawa J, Adachi T. [Peak flow values in assessment of global improvement rating in bronchial asthma]. Arerugi 1999;48:576-88
   PubMedGoogle Scholar
• Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001;86:203-10
   PubMed Web of Science ®Google Scholar
• O’Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001;86:397-404
   PubMed Web of Science ®Google Scholar
• Harnest U, Price D, Howes T, et al. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. J Asthma 2008;45:215-20
   PubMed Web of Science ®Google Scholar
• Wardlaw A, Larivee P, Eller J, et al. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004;93:49-55
   PubMed Web of Science ®Google Scholar